With a current price of $14.90, Karyopharm Therapeutics Inc. [NASDAQ:KPTI] is active in the Biotechnology industry, with a 5-day price swing of -6.64%.
For the year, the stock is trading -22.27%, while, as a point of reference, the S&P 500 is trading -2.43% YTD. Other data to note on this name is a price per sales number of 13.02.
The Bears are coming
Holding a Market Cap of $1.08 billion, Karyopharm Therapeutics Inc. has seen a trading range over the last year of $8.91-$29.61.
For the last five days, KPTI is down from its last closing price. The average shares trading hands each day is 1.56M, with average 10-day volume coming in at 1.37 million.
Using a Force Index Indicator is a good way to look at how strong actual buying and selling pressure is for KPTI. When we apply the Elder Force Index to Karyopharm Therapeutics Inc., we are seeing an Elder Force Indicator number of -1790143.2.
The company’s enterprise value has gone from $1.16B to $1.27B quarter-over-quarter. This could be an inflection point for the company, but either way we believe you should be adding them to your watchlist.
In the last quarter, KPTI made a profit of 33.12 million. Karyopharm Therapeutics Inc. also saw quarter revenue growth year over year of 34.80%. In addition, the company has operating cash flow of -$161.28 million.
Looking at popular technical indicators, the company’s 5-day moving average is 15.93 compared to the 50-day moving average of 15.15. So, we are clearly seeing an upward trajectory here.
The Relative Strength Index or RSI is an indicator ranging between 0 and 100 that traders use to determine if a stock is “overbought” or “oversold.” A strong uptrend tending to reach into the “overbought” status is above 70, while a downward trend will stay around the 30 mark. KPTI currently holds a 9-day RSI of 41.75%, while 100-day RSI stands at 48.46%.
Another indicator we believe is worth keeping tabs on is the Moving Average Convergence Divergence or MACD. Similar to the concept of the Force Index — on the basis of price momentum — the MACD gives traders a tool to measure the turning point of a stock even during rapid fluctuations in price. Buy and sell signals are determined by a stock’s relation to the zero line, so if a stock is above a zero line for many weeks it might be a “buy.” On the other hand, if a stock is below the zero line consistently, it might be one to stay away from. Also, if the MACD line reaches a peak and dips, its momentum may be waning. KPTI’s 9-day MACD is 0.08 and the company’s 100-day MACD stands at -1.61.
Another area that is important to analyze is insider moves and majority shareholders. While this is not always an error-free way to tell what the future holds for a stock, you can maybe gather important information from reading the tea leaves about who is buying and selling.
The major holders for this stock are 12.78% by insiders and 91.03% by institutions. Regarding institutional holdings, Avoro Capital Advisors LLC owns 9.53%, while the second top holder, Consonance Capital Management LP, currently owns 8.84%.
Over the last six months, insiders have sold 10,054 with the most recent transaction from Primiano Christopher Brett, EVP, CBO, GC & Secretary, with a sell at price 14.98 per share.
Overall, the recommended rating for KPTI is Strong Buy. Currently, the company has 10 analysts watching the stock, and the average quarterly earnings estimate is -0.7. Quarterly revenue estimates are averaging 23.16M with the high estimate reaching 36.75M and the low at 19.35M.